IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030.Diab Res Clin Pract. 2011; 94: 311-321
Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study.Diab Care. 1998; 21: 1167-1172
Mechanisms of diabetic complications.Physiol Rev. 2013; 93: 137-188
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.N Engl J Med. 1998; 339: 229-234
Metformin: new preparations and nonglycemic benefits.Curr Diab Rep. 2017; 17: 5
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Diab Care. 2015; 38: 140-149
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.BMJ. 2009; 339: b2535
- Higgins J.P.
- Thompson S.G.
Quantifying heterogeneity in a meta-analysis.Stat Med. 2002; 21: 1539-1558
Statistical aspects of the analysis of data from retrospective studies of disease.J Natl Cancer Inst. 1959; 22: 719-748
Meta-analysis in clinical trials.Control Clin Trials. 1986; 7: 177-188
Operating characteristics of a rank correlation test for publication bias.Biometrics. 1994; 50: 1088-1101
Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.J Clin Endocrinol Metab. 2013; 98: 668-677
Intensive glucose control and cardiovascular outcomes in type 2 diabetes.Heart Lung Circ. 2011; 20: 647-654
Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care.Eur Heart J. 2011; 32: 2247-2255
- Martin-Montalvo A.
- et al.
Metformin improves healthspan and lifespan in mice.Nat Commun. 2013; 4: 2192
Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance.Diabetes. 2005; 54: 1566-1572
The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.Diabetes. 2002; 51: 189-197
- Griffin S.J.
- Leaver J.K.
- Irving G.J.
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes.Diabetologia. 2017; 60: 1620-1629
Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis.Cardiovasc Diabetol. 2019; 18: 96
Repurposing metformin: an old drug with new tricks in its binding pockets.Biochem J. 2015; 471: 307-322
Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.J Biol Chem. 2000; 275: 223-228
- Owen M.R.
- Doran E.
- Halestrap A.P.
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.Biochem J. 2000; 348: 607-614
The AMP-activated protein kinase pathway–new players upstream and downstream.J Cell Sci. 2004; 117: 5479-5487
Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase.Diabetes. 2006; 55: 496-505
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner.Cell Metab. 2010; 11: 390-401
The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus.Curr Vasc Pharmacol. 2010; 8: 327-337
- El Messaoudi S.
- Rongen G.A.
- Riksen N.P.
Metformin therapy in diabetes: the role of cardioprotection.Curr Atheroscler Rep. 2013; 15: 314
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.Diab Care. 2002; 25: 2244-2248
All-cause and cardiovascular mortality following treatment with metformin or glyburide in patients with type 2 diabetes mellitus.Arch Iran Med. 2017; 20: 141-146
All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.Diab Obes Metab. 2014; 16: 231-236
Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.Ann Intern Med. 2012; 157: 601-610
Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study.J Am Heart Assoc. 2017; 6
Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register.BMJ Open. 2012; 2
Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.Diab Obes Metab. 2012; 14: 803-809
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.Diab Obes Metab. 2019; 21: 1199-1208
Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study.J Stroke Cerebrovasc Dis. 2014; 23: e99-e105
Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study.Diabetologia. 2015; 58: 50-58
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.Diabetologia. 2006; 49: 930-936
Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.Diab Obes Metab. 2010; 12: 757-765
Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.Diab Obes Metab. 2014; 16: 957-962
Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.J Manage Care Spec Pharm. 2014; 20: 895-903
- Hippisley-Cox J.
- Coupland C.
Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.BMJ. 2016; 354: i3477
Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients.Cardiovasc Diabetol. 2015; 14: 137